National Registry and Blood Bank of Patients With Liver Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00482365|
Recruitment Status : Completed
First Posted : June 5, 2007
Last Update Posted : August 19, 2013
RATIONALE: Gathering health information about patients with liver cancer over time may help doctors learn more about the disease and may help the study of cancer in the future.
PURPOSE: This clinical trial is developing a national registry and blood bank of patients with liver cancer.
|Condition or disease||Intervention/treatment|
|Liver Cancer||Other: biologic sample preservation procedure Other: medical chart review Other: Patient interview|
- Evaluate etiologic factors associated with hepatocellular carcinoma (HCC) in different ethnic groups and in different parts of the United States by developing a national registry of HCC patients.
- Survey stage and potential treatability of HCC patients referred to Vanderbilt University Hospital.
- Establish a serum repository for registry patients with samples to be used for future studies of the pathogenesis of chronic liver disease and HCC and for developing better diagnostic tests.
OUTLINE: This is a multicenter, cross-sectional database study.
Data are collected on patients diagnosed with hepatocellular carcinoma at Vanderbilt University Medical Center and at other participating hospitals or liver transplantation centers around the country for inclusion in a national registry of liver cancer patients. Registry data are collected at baseline and then every 6 months for up to 5 years. The data are derived from investigator interviews with patients and from medical chart review of routine medical care provided during the course of the study. Data are collected from all study sites and entered into a master database that includes information on patient demographics, diagnoses and staging details, treatment history, results of laboratory studies, and patient outcomes. Information derived from the registry is available to investigators at all study sites.
Patients in the registry also undergo blood collection at baseline. Blood samples are stored in a serum repository for evaluation in future studies related to liver disease, viral hepatitis, and liver cancer. A biological marker that may be analyzed is squamous cell carcinoma antigen immune complex (SCCA-IC).
PROJECTED ACCRUAL: A total of 1,500 patients will be accrued for the Vanderbilt University Medical Center study and up to 2,000 patients for the national study.
|Study Type :||Observational|
|Actual Enrollment :||151 participants|
|Official Title:||A National Registry of Patients With Hepatocellular Carcinoma|
|Study Start Date :||April 2002|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||August 2009|
Other: biologic sample preservation procedure
- Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US [ Time Frame: every 6 months up to 5 years ]A descriptive analysis will be done to describe the number of patients with HCC, their underlying etiology, correlation between etiology and demographic features and the outcome of various forms of therapy. Survival analysis will be done, comparing various forms of therapy while adjusting for stage of disease.
- Serum repository for registry patients [ Time Frame: At study entry ]blood samples will be drawn at the time of standard of care and stored.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00482365
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center - Cool Springs|
|Nashville, Tennessee, United States, 37067-1631|
|Vanderbilt-Ingram Cancer Center at Franklin|
|Nashville, Tennessee, United States, 37067|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Principal Investigator:||Sunil Geevarghese, MD||Vanderbilt-Ingram Cancer Center|